AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ELOX · NASDAQ · Biotechnology

Eloxx Pharmaceuticals (ELOX)

Develops ribosome-modulating medicines for nonsense-mutation kidney diseases.

$16.11

Pre-market+0.08 (+0.50%)

At close$16.03(+6.80%)

Watchlist

In millions of USD, except per-share figures

In millions	Q1 FY25Mar 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
	1	4	4
Research & development	1	2	3
	1	2	2
General & administrative	1	2	2
Operating income	−1	−4	−4
	0	0	0
Interest income	0	0	0
Interest expense	0	0	0
Other non-operating income	0	0	0
Income before tax	−2	−4	−5
Net income from continuing operations	−2	−4	−5
Net income	−2	−4	−5
EPS, basic	−$4.95	−$0.86	−$0.66
EPS, diluted	−$4.95	−$0.86	−$0.66
Weighted average shares, basic	0	4	7
Weighted average shares, diluted	0	4	7
EBITDA	−1	−4	−4
EBIT	−1	−4	−4